Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

James D Doecke; Cindy Francois; Christopher J Fowler; Erik Stoops; Pierrick Bourgeat; Stephanie R Rainey-Smith; Qiao-Xin Li; Colin L Masters; Ralph N Martins; Victor L Villemagne; Steven J Collins; Hugo Marcel Vanderstichele

doi:10.1186/s13195-021-00812-9

Retour

Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

Article de revue

Avec comité de lecture

Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

James D Doecke, Cindy Francois, Christopher J Fowler, Erik Stoops, Pierrick Bourgeat, Stephanie R Rainey-Smith, Qiao-Xin Li, Colin L Masters, Ralph N Martins, Victor L Villemagne, …

Alzheimer's research & therapy, Vol.13(1), pp.79-12

16/04/2021

DOI: https://doi.org/10.1186/s13195-021-00812-9

PMID: 33863377

Résumé

Alzheimer Disease - diagnosis

Amyloid beta-Peptides

Amyloid Precursor Protein Secretases

Aspartic Acid Endopeptidases

Australia

Biomarkers

Cognitive Dysfunction - diagnosis

Humans

Peptide Fragments

tau Proteins

CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration. Biomarkers for β-amyloidopathy (Aβ1-42, Aβ1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6). High biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability. Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.

Indicateurs

1 Consultations de la notice

Détails

Titre: Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods
Créateurs - sans rôle: James D Doecke - The Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia
Cindy Francois - ADx NeuroSciences, Ghent, Belgium
Christopher J Fowler - University of Melbourne, Melbourne, VIC, Australia
Erik Stoops - ADx NeuroSciences
Pierrick Bourgeat - The Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia
Stephanie R Rainey-Smith - Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia
Qiao-Xin Li - University of Melbourne, Melbourne, VIC, Australia
Colin L Masters - The University of Melbourne
Ralph N Martins - Edith Cowan University
Victor L Villemagne - Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
Steven J Collins - University of Melbourne, Melbourne, VIC, Australia
Hugo Marcel Vanderstichele - Biomarkable, Ghent, Belgium. hugo.vanderstichele@biomarkable.be
Détails de publication: Alzheimer's research & therapy, Vol.13(1), pp.79-12
Identifiants: 99158763909311
Unité académique: Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Langue: English
Type de ressource: Journal article